BridgeMD
New treatment option for Obesity
Official title A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ClinicalTrials.gov ID: NCT07321886
What this study is testing
What is Eloralintide?
Eloralintide is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for obesity.
Also referred to as LY3841136.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out how well eloralintide works and if it is safe for adults with obesity or overweight without type 2 diabetes.
- Who it's for
- Adults who are obese or overweight and do not have type 2 diabetes.
- What's involved
- Participants will receive eloralintide and will be monitored for their health and weight changes during the study.
- Time commitment
- The main phase lasts about 75 weeks, with an option to continue for another 2 years for some participants.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have Body Mass Index (BMI) at screening of the following:
- 30 kilogram per square meter (kg/m2) OR
- 27 kg/m2 with at least one of the following weight-related health conditions at screening:
- high blood pressure
- dyslipidemia
You likely can't join if
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was...
- Have type 1 diabetes or type 2 diabetes
- Have had within 90 days prior to screening:
- heart attack
- stroke
See the full eligibility criteria
- Have Body Mass Index (BMI) at screening of the following:
- 30 kilogram per square meter (kg/m2) OR
- 27 kg/m2 with at least one of the following weight-related health conditions at screening:
- high blood pressure
- dyslipidemia
- obstructive sleep apnea, or
- heart disease
- Have a stable body weight (\<5% body weight change) for 90 days prior to screening.
- Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes or type 2 diabetes
- Have had within 90 days prior to screening:
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening
The study team makes the final eligibility decision.
Where it's taking place
- Tuscaloosa, Alabama, United States
- Scottsdale, Arizona, United States
- Escondido, California, United States
- Fountain Valley, California, United States
- Palm Springs, California, United States
- Rolling Hills Estates, California, United States
- Sacramento, California, United States
- Santa Ana, California, United States
- Tustin, California, United States
- Waterbury, Connecticut, United States
- Atlantis, Florida, United States
- Miami, Florida, United States
- Mt. Dora, Florida, United States
- Pembroke Pines, Florida, United States
- Pensacola, Florida, United States
- St. Petersburg, Florida, United States
- Dunwoody, Georgia, United States
- Lawrenceville, Georgia, United States
- Stockbridge, Georgia, United States
- Honolulu, Hawaii, United States
+ 118 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tuscaloosa, Alabama, United States; Scottsdale, Arizona, United States; Escondido, California, United States; Fountain Valley, California, United States; Palm Springs, California, United States; Rolling Hills Estates, California, United States and 132 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.